Followers | 145 |
Posts | 27558 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, June 19, 2015 9:28:19 AM
Strategic acquisition to combine medical devices and pharmaceutical products to address multi-billion dollar markets in treating ophthalmic diseases
PETACH TIKVA, Israel, June 19, 2015 /PRNewswire/ -- OphthaliX Inc. (OPLI), a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT:CANF), announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.) in a stock-for-stock transaction.
Under the terms of the agreement, in exchange for I.V.S. becoming a wholly-owned subsidiary of OphthaliX, OphthaliX will issue to the sellers and option holders of I.V.S. at the initial closing such number of shares of OphthaliX common stock and OphthaliX options equal to an aggregate of approximately 14% of the issued and outstanding capital stock of OphthaliX on a fully diluted basis immediately following the initial closing. In addition, OphthaliX has agreed to issue to the sellers and option holders of I.V.S. such number of shares of OphthaliX common stock and OphthaliX options equal to an aggregate of approximately 11% of the issued and outstanding capital stock of OphthaliX on a fully diluted basis upon the attainment of certain milestones. The closing of the acquisition is subject to certain closing conditions including the raising of capital by OphthaliX and an up-listing of OphthaliX to a national securities exchange in the United States. No shares of OphthlaliX's parent company, Can-Fite BioPharma, will be issued as a part of this transaction.
I.V.S. develops breakthrough medical device technologies to improve sight, diagnose and offer therapy for a variety of ocular diseases including glaucoma, age related macular degeneration (AMD), diabetic retinopathy and oculo-motor pathologies, addressing multi-billion dollar markets. I.V.S. is developing two types of products: (1) an indoor eye tracking solution, attachable to any screen including TVs, computers, tablets, etc., that manipulates the image shown to the user in such a way as to best compensate for such user's specific clinical impairment; and (2) a goggles-based mobile device which generates high definition displays that are manipulated and moved based on the device's ability to track each eye individually, thus restoring mobility and independence to visually impaired people.
OphthaliX is committed to continuing its development program for its drug candidate CF101, a neuro-protective and anti-inflammatory drug, for the treatment of glaucoma. Patients are currently enrolled for the second segment of the Phase II study and are treated orally with CF101.
Upon initial closing, I.V.S. executives Ran Yam and Dan Oz will join OphthaliX's Board of Directors. Additionally, upon initial closing Ran Yam will be appointed Chief Executive Officer of OphthaliX and Dan Oz Chief Technology Officer, bringing their long and successful track records in the medical device field to the Company.
"We are thrilled to take this important step towards acquiring I.V.S and are excited about the potential of this acquisition as we pursue our strategy of re-positioning OphthaliX as a company that addresses substantial ophthalmologic markets through both medical devices and pharmaceutical products," stated OphthaliX Chairman and CEO, Dr. Pnina Fishman. "We welcome the I.V.S. team to OphthaliX."
Ran Yam, I.V.S. CEO added, "There are significant synergies between OphthaliX and I.V.S. and we believe that our combined pharmaceutical and medical device development program presents a compelling opportunity. The visions of the OphthaliX team and I.V.S. team are shared and we look forward to working together."
About CF101
CF101, an A3 adenosine receptor (A3AR) agonist, is a novel, first in class small molecule orally bioavailable drug which binds with high affinity and selectivity to the A3AR, which is known to be over-expressed in inflammatory cells. The drug acts as a neuro-protective agent and prevents apoptosis of retinal ganglion cells.
About OphthaliX Inc.
OphthaliX Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders.
Recent MIGI News
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for March 2024 • GlobeNewswire Inc. • 04/18/2024 11:00:53 AM
- Mawson Infrastructure Group Inc. Announces New Board Chair • GlobeNewswire Inc. • 04/15/2024 09:15:22 PM
- Mawson Infrastructure Group Inc. Reports Q4 and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 04/01/2024 10:05:07 AM
- Mawson Infrastructure Group Expands Co-Location Business • GlobeNewswire Inc. • 03/27/2024 12:50:58 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for February 2024 • GlobeNewswire Inc. • 03/19/2024 12:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:00:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/07/2024 02:43:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:25:47 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 02:37:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:50:55 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for January 2024 • GlobeNewswire Inc. • 02/16/2024 01:45:24 PM
- Mawson Infrastructure Group Inc. Executes Another Customer Co-Location Agreement • GlobeNewswire Inc. • 02/06/2024 02:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:50:32 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for December 2023 • GlobeNewswire Inc. • 01/16/2024 01:45:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 10:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:37:03 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for November 2023 • GlobeNewswire Inc. • 12/20/2023 09:35:29 PM
- Mawson Infrastructure Group Inc. Executes New Customer Co-Location Agreement • GlobeNewswire Inc. • 12/19/2023 10:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:03 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM